SGC
NVO

Slocum, Gordon & Co’s Novo Nordisk NVO Stock Holding History

Slocum, Gordon & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42
Closed -$2.9K – 105
2025
Q2 		$2.9K Sell
42
-2
-5% -$136 ﹤0.01% 111
2025
Q1 		$3.05K Buy
+44
New +$3.63K ﹤0.01% 122

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Slocum, Gordon & Co's NVO Position: Q3 2025 in Review

Slocum, Gordon & Co sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 42 shares — an estimated $2.9K sold.

Slocum, Gordon & Co first reported a position in NVO in Q1 2025 and held it in 2 quarters. The position peaked at $3.05K in Q1 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Slocum, Gordon & Co reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Slocum, Gordon & Co sold 42 Novo Nordisk shares in Q3 2025, an estimated $2.9K.
  • Slocum, Gordon & Co first reported a position in Novo Nordisk in Q1 2025 and held it in 2 quarters.
  • Slocum, Gordon & Co's Novo Nordisk position peaked at $3.05K in Q1 2025.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Slocum, Gordon & Co's 13F filing for Q3 2025, filed 17 Oct 2025.